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A cross-sectional study on the burden and
impact of migraine on work productivity
and quality of life in selected workplaces in
the Philippines
Nel Jason Haw1,2* , Ian Theodore Cabaluna2, Germaine Erika Kaw2, Joanna Feliz Cortez2, Maria Pamela Chua3 and
Kristel Guce3

Abstract
Background: Migraine imposes a substantial personal and economic burden to many working age individuals. This
study aimed to evaluate the burden and impact of migraine on work productivity in selected workplaces in the
Philippines.
Methods: A cross-sectional survey was conducted among employees suspected or diagnosed with migraine
February to May 2020. Volunteer employees were screened for migraine using the ID-Migraine™ test. Eligible
employees were tested for migraine severity and impact on work productivity using the Migraine Disability
Assessment (MIDAS) questionnaire. Quality of life was measured using the Short Form-36 (SF-36) questionnaire and
additional questions on triggers, coping mechanisms, workplace assistance, and health care utilization were asked.
Multiple logistic regression was used to identify significant predictors of migraine disability (high – MIDAS Grade III/
IV vs. low – MIDAS Grade I/II). Differences in quality of life scores by migraine disability were measured using
multiple linear regression. Productivity costs lost to migraine disability were calculated as the number of days lost
to migraine multiplied by the self-reported wage rate, and costs according to migraine severity were measured
using a two-part generalized linear model.
(Continued on next page)
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Results: From around 24,000 employees who were invited to participate in the survey, 954 respondents provided
consent and attempted to respond to the survey resulting to a response rate of around 4.1%. A total of 511
positive migraine screens were included in the final sample. Females comprised two-thirds of all positive migraine
screens and were more likely to have high migraine disability (odds ratio: 1.60, 95% CI: 1.03–2.49) than males. Those
with high migraine disability scored lower on role limitations compared to those with low migraine disability. Stress
and looking at computer screens were cited as the top trigger for migraine, while sleeping enough hours and
getting a massage were cited as top coping mechanisms. Three in four (77%) visited their company clinic within
the past 3 months, which meant that most doctors seen for migraine-related symptoms were general practitioners.
Five in six (85%) took medication for migraine, almost all of which were over-the-counter medications. Mean annual
productivity costs lost due to migraine disability were PHP27 794 (USD556) per person.
Conclusion: Migraine poses a significant threat to work productivity in the Philippines. Many opportunities, such as
disease management and introduction of alternative options for migraine treatment, may be introduced to help
address these issues.
Keywords: Migraine, Burden of disease, Cost of illness, Quality of life, Health care utilization, Philippines, Workplace

Introduction
Migraine is a neurological disorder recognized as one of
the leading causes of disability in the world, estimated to
impact anywhere between one in ten [1] and one in six
individuals [2]. While several population-level studies on
migraine have been conducted in the past few years,
there remain countries with little information on the
burden of migraine, specifically in the Asia-Pacific region
[2]. A systematic review and meta-analysis on chronic
migraine found only seven population-level studies in
the Asia-Pacific region estimating chronic migraine
prevalence to be approximately 6–17 people per 1000
population [3]. In the Philippines, the last known
national-level migraine prevalence survey was in 2003,
which found that 7.9% of the population screened positive for migraine [4]. However, in 2017, the Institute for
Health Metrics and Evaluation (IHME) reports that
headache disorders which include migraine has a prevalence estimate of about 17.3% [5].
Migraine is associated with significant impact on daily
living, such as work, school, and personal activities [6].
Migraine patients consistently report poorer quality of
life scores than healthy individuals on aspects of physical
well-being, while chronic migraine patients consistently
report poorer quality of life scores than episodic migraine patients on aspects of emotional well-being [7].
Additionally, the expectation of worry on the next migraine attack is in itself negatively affecting work productivity and quality of life [8].
Sex and age are significantly associated with migraine
burden, with females at least twice as likely to report
having migraine [1] and working-age individuals more
likely to report having migraine than younger or older
individuals [9]. This implies that migraine poses a significant economic burden and various studies in the past
have tried to quantify the economic impacts of migraine.

The European Eurolight project estimated that more
than 90% of economic losses associated with migraine
were attributable to indirect costs such as sick days and
reduced work productivity as compared to less than 10%
of direct costs such as medicines and outpatient consultation [10]. A systematic review from the United States
found that on average around 2 to 3 workdays per
month were lost due to migraine, with women reporting
twice more workdays affected than men [11]. A Malaysian study found similar results with mean days affected
by migraine being 5.6 days over the past 3 months
among banking sector employees, with monetary losses
potentially reaching as much as USD3000 annually for
those with the most severe forms of migraine [12]. In a
literature search, this was the only published study found
to present data on the burden of migraine in the Asia
Pacific region.
Given this, the present study assessed the burden and
impact of migraine and work productivity and daily activities in selected workplaces in the Philippines. Focusing on those having migraine, this study explored the
migraine patient journey regarding the frequency and severity of migraine attacks, triggers in the workplace,
workplace assistance programs, availability and
utilization of health care services, and quality of life. Finally, this study also measured monetary estimates on
lost productivity.

Methods
Study design and setting

A cross-sectional study was conducted among employees of 12 companies in the Philippines across various industries, such as telecommunications, holdings
groups, business process outsourcing, and finance, from
February to May 2020. The survey was conducted online
and through physical booths at company clinics,
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depending on the preference of human resources departments of the participating companies. All employees in
these companies, estimated at 24,000, were invited to
participate in the survey. To maximize survey participation rate, companies were selected based on the following criteria: having more than 50% share of females in
the workforce, having generous employment benefits
such as private health insurance and medicine allowances, and known for having a tough environment that
may trigger migraine attacks, such as prolonged computer usage (Fig.1).
All interested participants in the survey underwent an
informed consent process. In the online version of the
survey, the first page introduced a short and long version
of the informed consent form, and participants had three
options to proceed: provide consent and proceed with
the questionnaire, decline to participate and the survey
ended, and a free text space to ask any clarificatory questions about the survey, with a member of the research
team providing a response within 24 h via short messaging service (SMS). Since mobile phones are not registered to specific individuals and geographic locations in
the Philippines, this ensured that participants remain anonymous while still reachable by the survey team to answer their questions.
Those who provided consent then answered a series of
eligibility and migraine screening questions. Those

Fig. 1 Study population flowchart
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eligible to answer the survey were permanent residents
of the Philippines, who were age 18 or older at the time
of the survey and worked at least 40 h a week in their
company. Those who self-reported as having been diagnosed with migraine by a licensed medical professional,
and those who screened positive using the ID Migraine™
Test, were considered as positive migraine screens and
comprised the study sample who answered the full
questionnaire. The ID Migraine™ Test consists of three
questions on commonly reported migraine symptoms –
nausea, limited ability to do daily tasks, and photosensitivity – and at least two symptoms must be reported for
a positive screen. The test has been validated in multiple
contexts and has been used in previous migraine
population-level studies because of its simplicity and accuracy compared to a clinical diagnosis [13–15]. A systematic review found that the pooled sensitivity of the
test is 84% (95% confidence interval (CI): 75% - 90%)
and specificity is 76% (95% CI: 69% - 83%) [13].
Questionnaire and study variables

The questionnaire was divided into the following sections [1]: socio-demographic information [2]; the Migraine Disability Assessment (MIDAS) Questionnaire,
which measured migraine severity across four grades [3];
the Short-Form 36 (SF-36) Questionnaire, which measured quality of life across eight domains [4]; health care

Haw et al. The Journal of Headache and Pain

(2020) 21:125

utilization, which looked at outpatient consultations,
emergency room (ER) visits, hospitalizations, and medicines utilization; and [5] triggers and coping mechanisms
in the workplace against a suspected migraine attack;
and [6] assistance provided in the workplace, which
asked actual support mechanisms and perceived usefulness of a wide range of support mechanisms, regardless
of their availability in the workplace.
The burden of migraine was measured as the MIDAS
Score, which is measured as the total number of workdays lost to migraine over a three-month period. The
MIDAS Score may be coded into MIDAS Grades, indicating migraine severity: Grade I (0 to 5); Grade II (6 to
10); Grade III (11 to 20); and Grade IV (21 and above).
The MIDAS Score may also be disaggregated into two:
number of workdays lost due to migraine, also known as
absenteeism; and number of workdays with impaired
work productivity due to migraine, also known as presenteeism. Daily costs attributable to absenteeism were
calculated as absenteeism multiplied by the daily rate,
while daily costs attributable to presenteeism were calculated as presenteeism multiplied by the daily rate. The
daily rate was calculated as the self-reported gross
monthly income divided by 22 working days. Annual
economic costs of migraine were calculated as the daily
costs attributable to absenteeism and presenteeism
multiplied by 22 working days per month then multiplied by 12 months per year. The computed economic
costs was converted to USD based on the conversion
rate from the Central Bank of the Philippines during the
study period [16].
Data analysis

Descriptive statistics were reported for overall MIDAS
Score and MIDAS Grade, SF-36 quality of life score
across each of the eight domains, workplace triggers,
coping mechanisms, health care utilization, assistance in
the workplace, and economic costs. MIDAS Grade was
dichotomized between high migraine disability (MIDAS
III/IV) and low migraine disability (MIDAS I/II). Chisquare tests and student t-tests were done to determine
differences in demographic information and migraine
disability.
To determine predictors of migraine disability, adjusted odds ratios (OR) and their 95% confidence intervals (CI) were calculated for high vs. low migraine
disability for the following socio-demographic factors:
gender, age, educational attainment, employee rank, and
gross monthly income from the company. The final multiple logistic regression model included all covariates except gross monthly income given its collinearity with
employee rank.
Migraine disability (high/low) was used as a predictor
for SF-36 quality of life score, adjusted for gender, age,
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educational attainment, and employee rank using multiple linear regression, and with health care utilization
adjusted for the same covariates using multiple logistic
regression. Finally, given that not all migraine positive
screens reported absenteeism and presenteeism, a twopart model was used to determine the economic costs of
migraine between low and high migraine disability: the
first part was a logistic regression model that determined
the probability of reporting any economic cost of migraine, while the second part was a generalized linear
model (GLM) fit with a log link function and gamma
(for absenteeism) or Poisson distribution (for presenteeism and total days and cost lost to migraine), with the
function and distribution confirmed using the box-cox
test and modified Park test, respectively [17]. All analyses were conducted using Stata IC 15.1 (StataCorp,
College Station, TX).

Results
A total of 954 respondents provided consent and
attempted to respond to the survey, or a response rate of
around 4.1%. Of those, 511 screened positive for migraine, with 193 reported they have been diagnosed with
migraine by a licensed medical professional and the rest
screening positive using the ID Migraine™ Test. Of those
who screened positive with the ID Migraine™ Test, 270
(84.9%) reported symptoms of nausea, 282 (88.7%) reported the headaches limited their ability to do daily
tasks, and 284 (89.3%) reported that light was bothering
them when they had headaches. MIDAS Grade was
available for 372 positive migraine screens, with 100
(26.9%) reporting Grade I, 64 (17.2%) reporting Grade II,
93 (25.0%) reporting Grade III, and 115 (30.9%) reporting Grade IV (Fig. 1).
Table 1 summarizes the demographic information of
positive migraine screens, disaggregated by migraine disability severity. Two in three (67.5%) were female,
around half (48.9%) were from the ages of 25 to 34 years
old, four in five (80%) were college graduates, around
half (53.2%) were rank and file employees, and about
two in five (36.6%) earned less than PHP20 000
(USD400) monthly.
Between low and high migraine disability, differences
in demographics were apparent in females, where a
higher proportion of females was reported among those
with high migraine disability (68.2%) than low migraine
disability (57.3%, p = 0.029). The reverse was true for
college graduates (75.0% for high v 85.3% for low, p =
0.014). These relationships remained after adjusting for
age and employee rank. Females had 1.6 times the odds
of having high disability migraine (95% CI: 1.03–2.49)
than males, while college graduates had around half the
odds of having high disability migraine (0.55, 95% CI:
0.31–0.96) than non-college graduates. Age, employee
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Table 1 Demographics of positive migraine screens and association with high migraine disability (n = 511)
Overall
(n = 511)

Low migraine
disability (MIDAS I/II)
(n = 164)

High migraine disability pAdjusted odds ratio (95% CI)
(MIDAS III/IV)
value
(n = 208)

Females, n (%)

345
(67.5%)

94 (57.3%)

142 (68.2%)

0.029 1.60 (1.03–2.49)

Age, mean (SD)

31.6 (7.5)

32.3 (7.7)

31.5 (7.3)

0.287 0.98 (0.96–1.02)

140 (85.3%)

156 (75.0%)

0.014 0.55 (0.31–0.96)

Finished college, n (%) 406
(79.4%)
Employee rank, n (%)

0.293

Rank and file

272
(53.2%)

79 (48.2%)

117 (56.2%)

ref.

First-level
management

139
(27.2%)

50 (30.5%)

52 (25.0%)

0.91 (0.54–1.53)

Middle & senior
management

100
(18.6%)

35 (21.3%)

39 (18.8%)

0.84 (0.47–1.50)

Gross monthly
income (PHP), n (%)

0.193 (not considered in final regression model due to
collinearity with employee rank)

Less than 20,000

187
(36.6%)

53 (32.3%)

74 (35.6%)

20,000 to 29,999

166
(32.5%)

50 (30.5%)

76 (36.5%)

30,000 to 39,999

62 (12.1%)

22 (13.4%)

26 (12.5%)

40,000 and above

158
(18.8%)

39 (23.8%)

32 (15.4%)

Notes: 1. Models were adjusted for gender, age, educational attainment, and employee rank; 2. PHP: Philippine Pesos, Conversion rate approximately PHP50 =
USD1; 3. MIDAS Grade data available for 372 of 511 positive migraine screens

rank, and gross monthly income were not associated
with high migraine disability (Table 1).
Quality of life was significantly lower among those
with high migraine disability than those with low migraine disability across all eight SF-36 domains, after
adjusting for gender, age, educational attainment, and
employment rank (Fig. 2). Quality of life scores were at
least 10 points lower among those with high migraine
disability, out a total score of 100. The two highest differences were found in role limitations, both physically
and mentally (− 34.8 and − 24.9, respectively, p < 0.0001).
Around one in five respondents (21.6%) reported
worrying often or constantly about the next headache
happening in the workplace. About 72 % (72.7%) reported worrying sometimes about the next headache
while only 5.7% did not report worrying about the next
headache. Respondents identified multiple workplace
triggers, the top two of which were stress/heavy workload and looking at computer screens for too long (Fig. 3,
panel A). They also identified multiple coping mechanisms, such as sleeping enough hours and getting a massage (Fig. 3, panel B). Only 1.7% did not identify any
triggers, while only 4.9% did not identify any coping
mechanism.
Around two in three (63.8%) were open about discussing their migraine condition to others. More than half
(55.8%) reported that their workmates were aware of

their condition, while two in five (43.1%) reported that
their supervisor was aware of their condition.
In terms of support provided by employers for migraine, three-fourths (76.9%) reported having company
clinics available at their workplace, with about twothirds of all respondents (61.5%) finding those consultations useful (Fig. 3, panel C). Only 17.2% of all respondents reported having a safe/dark room, but
about half (48.3%) of all respondents found having a
safe/dark room useful in the workplace. A safe/dark
room is a separate quiet room available in some
workplaces to serve as a place for employees to rest
especially at the onset of a migraine attack. Similar
discrepancies in proportions were found for other
support programs, such as educational materials about
migraine, disease management programs, and digital
tools such as symptom tracking apps.
In the past three months, about two in three
(61.8%) reported using their company-provided health
insurance and medicines allowance benefits to pay for
migraine-related services. Of those, one in four
(25.4%) reported having outpatient consults with a
physician regarding migraine-related symptoms (Fig. 4,
panel A). Of those, 70.2% sought a general practitioner (GP) at least once, 41.5% sought an ophthalmologist at least once, 34.0% an ear, nose, throat
(ENT) specialist at least once, and 17.0% a neurologist
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Fig. 2 Adjusted differences in Short Form-36 (SF-36) quality of life scores between low and high migraine disability. Notes: Models were adjusted
for gender, age, educational attainment, and employee rank

at least once (Fig. 4, panel B). Five in six (85.2%) reported taking some form of medication, majority of
which were over-the-counter medications, e.g. paracetamol, ibuprofen (74.1%). Only a few respondents
reported taking prescriptive acute therapy, e.g. triptans (0.6%) and preventive therapy, e.g. atenolol
(2.5%) (Fig. 4, panel C). Finally, one in five (20.4%)
reported having undergone laboratory tests in the past
three months, one in three (30.3%) reported visiting
the hospital emergency room for headache symptoms
in the past 12 months, and one in six (17.6%) reported being hospitalized for a migraine emergency in
the past 12 months.
Migraine disability was significantly associated with
some health care utilization variables. Those with high
migraine disability were more likely than those with low
migraine disability to consult a doctor within the past
three months (OR: 3.11, 95% CI: 1.78–5.43), undergo a
laboratory test in the past three months (OR: 1.84, 95%
CI: 1.03–3.27), and visit the emergency department during the past 12 months (OR: 2.09, 95% CI: 1.25–3.48)
(Table 2).
On average, those with low migraine disability reported around two days affected by migraine over a
three month period (1.92, 95% CI: 1.61–2.24) and nine
days or more than four times more for those with high
migraine disability (8.97, 95% CI: 8.49–9.46) (Table 3).
Monthly costs on average lost due to migraine
amounted to PHP2 316.2 (USD46) (95% CI: 2232.9–

2399.5). Costs significantly differed between migraine
disability: monthly costs lost due to migraine for those
with low disability averaged around PHP865.1 (USD17)
(95% CI: 754.3–975.9) while costs quadrupled for those
with high disability at PHP3 440.8 (USD69) (95% CI:
3323.4–3558.3). These costs, when annualized, translate
to approximately PHP27 794.4 (USD556) per person for
everyone with migraine, PHP10 381.2 (USD207) per person for those with low migraine disability, and PHP41
289.6 (USD826) per person for those with high migraine
disability.

Discussion
This study provided a comprehensive view of how migraine affects employees in selected workplaces in the
Philippines. As much as nine days of work may be affected over a three-month period, or about 10% of all
employee work hours, for those with the most severe
forms of migraine. This finding is in the middle of previously reported estimates in other contexts. This is higher
than the mean of nine days for Malaysia [12], but lower
than the 45 days reported in the United States over the
same time period [18]. A systematic review in 2011
found the range of workdays missed ranges from 0.23 to
16.4 across multiple studies [7].
On the other hand, the economic costs lost due to migraine was much lower than previously reported in
upper middle income and upper income countries,
where estimates ranged upwards of USD1 000 per
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Fig. 3 Workplace conditions and support for migraine

employee annually [6, 10, 12]. In this study, the mean
annual cost was at USD500 per employee for those with
low migraine disability and USD800 per employee for
those with high migraine disability. This is because majority of the respondents in the study only had monthly
incomes of less than USD600, which represents the median household income in the country [19], but much
lower than median household incomes of richer countries. Regardless, relative to household income, these
costs remain significant to Filipino employees and their
families.
Presenteeism played a bigger role than absenteeism in
workplace productivity losses, reflecting results from
other countries [12, 20]. In this study, those with high
migraine disability were only expected to take a sick
leave for about 12 days a year due to migraine. Philippine labor law does not guarantee paid sick leave, but instead requires a minimum of five days of paid leave for
whatever reason, although in practice employees receive
more days of paid leave as a function of company benefits or collective bargaining agreements [21]. Therefore,
this does not fully explain why absenteeism was less

prevalent than presenteeism especially that the companies participating in the study provided generous company benefits such as more days of paid sick leave.
Other studies did not provide potential explanations for
this as well [12, 20], and further research is needed to
understand the motivating factors behind why those
with migraine choose to work despite experiencing
symptoms that affect their work productivity. Regardless,
higher rates of presenteeism may reflect worsening of
migraine over the long term, and exacerbate to stress,
which was cited as the top migraine workplace trigger,
and introduce a positive feedback loop of stress and migraine that will only increase economic losses and
poorer quality of life over time [22].
There are many opportunities to address migraine better in the workplace, and the companies selected in this
sample have already implemented some. Since all employees in the sample had generous company-provided
private health insurance and medicine allowances, health
care utilization rate for migraine was higher than the national health care utilization rate for any type of service,
which was 8% based on the 2017 Demographic and
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Fig. 4 Health care utilization for migraine-related services

Health Survey [23]. The types of doctors sought for consultation also reflected this high company benefit
utilization rate, since GPs are readily accessible in the
in-house clinics of these companies, which are required
by occupational health and safety laws in the Philippines,
and neurologists were not commonly sought since services by neurologists are not covered by private health
insurance plans. The frequency of ophthalmology consultations and desire for a safe/dark room in the workplace is reflective of prolonged computer usage, which
was cited as one of the top triggers for migraine.
The high intake of medicines may be a function of
utilization of company medicine allowances, and some
companies also subscribe to pharmacy benefit managers
that handle bulk medicine fulfillment based on a set formulary. However, use of prescriptive acute and preventive therapies remain very low, and this may be because
employees do not receive enough information on migraine. About two in five employees with migraine
would like more educational materials and migraine disease management programs available in their workplace,
but currently less than 5% of employees report these being available. Health education on migraine may present

opportunities to introduce holistic prevention and wellness, as well as alternative treatment options, such as
preventive medications, for migraine that provide more
than symptom relief for headaches.
Additionally, disease management programs should be
tailored towards specific socio-demographic groups. This
study did not find significant associations between age
and migraine disability, which was more apparent in
other studies [1, 2]. This is likely because the study sample comprised of younger adults, and this is expected
given the current median age of the Philippines is
around 24 years old [24]. On the other hand, females
were more likely to have high migraine disability than
males, which was consistent with results from other
studies [1, 2, 7, 12]. Other studies have hypothesized that
there may be biological factors, sociological factors and
health-seeking behavioral factors involved [6, 11], but
further research is needed to understand these differences in the Philippine context. Finally, higher education
seemed to be a protective risk against high migraine disability, a finding also seen in other studies. These studies
hypothesized that education may be a proxy indicator
for lifestyle and socioeconomic status, which is
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Table 2 Associations of health care utilization and workplace productivity losses with migraine disability (high or MIDAS III/IV vs low
or MIDAS I/II)
Odds ratio

Standard
error

p-value 95% confidence
interval

Consulted a doctor in the past 3 months

3.11

0.88

<
0.0001

1.78–5.43

Took medication in the past 3 months

1.67

0.58

0.137

0.85–3.30

Undergone lab tests in the past 3 months

1.84

0.54

0.038

1.03–3.27

Visited emergency department during the past 12 months

2.09

0.54

0.005

1.25–3.48

Hospitalized during the past 12 months

1.85

0.60

0.058

0.98–3.47

Reported at least 1 day of absenteeism in the past 3 months

6.63

1.65

<
0.0001

4.07–10.81

Reported at least 1 day of presenteeism in the past three months

2.49

0.34

<
0.0001

1.83–3.15

Reported at least 1 day of absenteeism or presenteeism in the past 3
months

2.73

0.41

<
0.0001

1.93–3.54

Health care utilization

Workplace productivity losses
Logistic regression (part 1) of two-part model

Generalized linear model with log link family and gamma distribution for absenteeism and Poisson distribution for presenteeism and total workdays lost
to migraine (part 2) of two-part model
Marginal
effect

Standard
error

p-value 95% confidence
interval

Number of days of absenteeism in the past 3 months

2.67

0.33

<
0.0001

2.04–3.31

Number of days of presenteeism in the past 3 months

5.08

0.31

<
0.0001

4.48–5.69

Total number of days lost due to migraine in the past 3 months

8.08

0.39

<
0.0001

7.31–8.86

Monthly costs due to absenteeism (PHP)

974.3

118.3

<
0.0001

742.5–1206.1

Monthly costs due to presenteeism (PHP)

1889.4

39.0

<
0.0001

1813.0–1965.8

Total monthly costs due to migraine (PHP)

2982.2

52.3

<
0.0001

2879.7–3084.6

Notes: 1. Models were adjusted for gender, age, educational attainment, and employee rank; 2. Workplace productivity losses were assessed using a two-part
model, where the first part measured the likelihood of reporting at least a day lost to migraine, and the second part measuring the number of days and
associated costs lost due to migraine for those reporting at least a day lost to migraine; 3. PHP: Philippine Pesos, Conversion rate approximately PHP50 = USD1

Table 3 Marginal effects of work productivity losses and economic costs due to migraine
Low migraine disability (95% CI)

High migraine disability (95% CI)

Number of days of absenteeism in the past 3 months

0.70 (0.50–0.89)

3.20 (2.75–3.65)

Number of days of presenteeism in the past 3 months

1.24 (0.99–1.48)

5.75 (5.36–6.14)

Total number of days lost due to migraine in the past 3 months

1.92 (1.61–2.24)

8.97 (8.49–9.46)

Monthly costs due to absenteeism (PHP)

263.6 (187.9–339.4)

1151.1 (984.7–1317.6)

Monthly costs due to presenteeism (PHP)

605.6 (514.9–696.3)

2279.6 (2185.3–2373.9)

Total monthly costs due to migraine (PHP)

865.1 (754.3–975.9)

3440.8 (3323.4–3558.3)

Notes: Adjusted for gender, age, educational attainment, and employee rank; workplace productivity losses were assessed using a two-part model, where the first
part measured the likelihood of reporting at least a day lost to migraine, and the second part measuring the number of days and associated costs lost due to
migraine for those reporting at least a day lost to migraine; PHP: Philippine Pesos, Conversion rate approximately PHP50 = USD1
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associated with increased exposure to migraine triggers
outside the workplace such as heavy traffic during commute and poor living conditions [25, 26]. This hypothesis may also be supported by the study’s results, since
those with high migraine disability had the greatest difference in quality of life score on domains related to
physical and emotional role limitations.
Altogether, an economic case for more expensive forms
of migraine prevention and treatment may be built based
on the results of this study. Given that the workplace burden is significant and there are companies willing to provide generous health benefits for their employees,
treatments may be justified on the expected savings from
productivity losses. However, further economic research is
needed to gauge the willingness to pay of these companies
to integrate those treatments in their medicine allowance
formulary or private health insurance plans, and any migraine treatment must also be assessed on factors such as
efficacy and cost-effectiveness. Employers must also be educated on the burden and impact of migraine in the workplace, and results from this study may begin that
important conversation for the benefit of employees and
companies overall.
Limitations

The study had some limitations. First, the sample is not
representative of all workplaces in the Philippines given
the selection criteria and willingness of employers to
participate in the study. The researchers tried to address
this by reaching out to more than 100 companies to participate in the survey, with 12 eventually included in the
final sample. Non-response bias among the selected
companies could also not be assessed, as the researchers
did not have access to company employee demographic
information that could be used for weighting and adjustment for bias. Second, some companies did not want to
be identified even with their industry, so analyses could
not be stratified by industry. Third, the variables were all
self-reported by the respondent, so a definitive migraine
diagnosis was not made in this study, and other variables
such as health care utilization history could not be independently verified because all responses were anonymized. Nonetheless, this study provided meaningful
data for the selected industries and may inform initiatives and programming for migraine health care.
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with low migraine disability across all eight SF-36 domains. The two highest differences were found in role
limitations, both physically and mentally. There are
companies in the Philippines that seems to provide
ample support for medical consultations through their
employee benefits programs, but there are opportunities
to implement other interventions such as prevention
and wellness programs. Most medication taken for migraine remain OTC medicines for symptom relief, and
further research is needed to gauge willingness of employers to pay for preventive medication for migraine.
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Conclusion
Migraine poses a significant burden to employee productivity in the Philippines, with annualized costs due to
migraine costing as much as PHP40 000 (USD826) per
person for those with high migraine disability and
PHP10 000 (USD200) per person for those with low migraine disability. Quality of life was significantly lower
among those with high migraine disability than those
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